Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease

Graves' disease (GD) is an autoimmune disorder caused by autoantibodies against the thyroid stimulating hormone receptor (TSHR) leading to overstimulation of the thyroid gland. Thyroid eye disease (TED) is the most common extra thyroidal manifestation of GD. Therapeutic options to treat TED are...

Full description

Bibliographic Details

Published in:	Frontiers in endocrinology (Lausanne) Vol. 14; p. 1211473
Main Authors:	Gulbins, Anne, Horstmann, Mareike, Daser, Anke, Flögel, Ulrich, Oeverhaus, Michael, Bechrakis, Nikolaos E., Banga, J. Paul, Keitsch, Simone, Wilker, Barbara, Krause, Gerd, Hammer, Gary D., Spencer, Andrew G., Zeidan, Ryan, Eckstein, Anja, Philipp, Svenja, Görtz, Gina-Eva
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 26.06.2023
Subjects:	autoimmune disorder Endocrinology Graves’ disease (GD) IGF-1R inflammation linsitinib thyroid eye disease (TED) Graves’ disease (GD) thyroid eye disease (TED) IGF-1R inflammation autoimmune disorder linsitinib
ISSN:	1664-2392, 1664-2392
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!